DR. MCEWEN: Yes, I had a few that I thought were over-arching. Some of them we touched on already. I think, again, I just want to reiterate that I think NARMS is an excellent program and all the groups presented an impressive amount of information and effort that is just unbelievable. I think just keep up the good work.

It seems, perhaps, most obvious that there needs to be better integration of the three areas. There is a lot of that already happening, but there is always room for improvement. I think this cuts across all the things that we have talked about.

Goal setting, setting objectives, sampling issues, design issues, testing issues, data analysis and interpretation. So that is going to be tough in some ways, especially, when it gets to interpretation and summary reports. But I think that has to happen to be really effective.

It seems to me there are some management issues that need to be considered in order to achieve that. And I think a point was made a couple of times, that there needs to be better coordination. And it seems to me it probably calls for sort of one voice to champion NARMS and to have some decision-making capabilities.

So it seems to me that, given that funding comes from FDA and the major, kind of over-arching goal in my mind, at least, of NARMS is antimicrobial resistance and how animal use of drugs effects that, that FDA would be a -- that CVM would be a logical place for that.

So I think we need to have somebody who can sort of take on a leadership role. And it seems to me that since he is not here today, it is easy to say, somebody like Dave White would be kind of a good example of somebody to take that on. So I think that is something to consider.

I already mentioned, and others have, that we need to kind of look at the objectives. They will be sort of NARMS-wide objectives, and then sort of area-specific ones that should relate to those over-arching objectives.

I think, again, a missing component in all of this is antimicrobial use information in animals and in people. And that would be something to strive for.

DR. YOUNGMAN: Thank you very much. Are there other general comments that someone would like to make? Sue.

DR. KOTARSKI: I had mentioned it before, but I would like to echo the sentiment of a steering committee or an advisory committee to work through over the years as a stopping point to reflect. I think that that is a good idea.

DR. YOUNGMAN: Thank you.

DR. MILLER: I agree with that point, and I would ask that you extend it internationally as well so that you have international representation involved.

DR. YOUNGMAN: Thank you very much.

Okay, I guess that wraps up our comments. Again, thank you very much to all of the attendees, the presenters, and the panelists. Thank you for all of your comments, we really appreciate them. Thank you very much.

Concluded-11:51am